Immunotherapy and heart risk study for skin cancer
Part of Heart & circulation clinical trials.
This study looks at whether certain immunotherapy drugs (nivolumab, pembrolizumab, or ipilimumab) affect the heart in people with skin cancer. You will have special heart imaging to check for any early signs of heart problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have skin cancer and are about to start treatment with one of these drugs: nivolumab, pembrolizumab, or ipilimumab.
- You can travel to Sunnybrook Hospital in Toronto for heart imaging.
- You are willing to give informed consent.
- You do not have a history of heart disease (like heart failure, heart attack, or irregular heartbeat).
- You are not pregnant and do not have severe kidney problems or a pacemaker.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
This study looks at heart health in people who have finished immunotherapy for melanoma. It uses MRI scans to check for any heart problems that may have developed after treatment.
This trial studies whether immunotherapy drugs (called immune checkpoint inhibitors) affect the small blood vessels of the heart. If you have breast cancer or lung cancer and are starting a specific treatment plan, you may be asked to have a special heart scan before and during therapy.
This study uses heart MRIs to monitor women with gynecologic cancers who are about to start immunotherapy. The goal is to detect early signs of heart problems so doctors can take action quickly.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
Hear when a new Cardio-Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.